07.02.2013 Views

Final Program in it's entirety - MyGirlsBlood

Final Program in it's entirety - MyGirlsBlood

Final Program in it's entirety - MyGirlsBlood

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Posters, Tuesday and Wednesday<br />

Index of Poster Presenters cont’d<br />

29P10<br />

The Year <strong>in</strong> Review: Describ<strong>in</strong>g Prophylaxis and Adherence<br />

<strong>in</strong> Children with Severe Hemophilia A Us<strong>in</strong>g Patient Infusion<br />

Diaries<br />

Bos C, Chan A, Webert K, Almonte T, Decker K, Goldsmith R<br />

McMaster Hemophilia Cl<strong>in</strong>ic, Hamilton ON, Canada<br />

29P11<br />

Prophylaxis with rFVIIa Three Times a Week for Patients with<br />

Severe Hemophilia and Inhibitors: A S<strong>in</strong>gle Centre Experience<br />

Cermelj M, Gerardo P, Pollola J<br />

Department of Haemophilia, Instituto William Osler, CABA,<br />

Buenos Aires, Argent<strong>in</strong>a<br />

29P12<br />

Turn<strong>in</strong>g Severe <strong>in</strong>to Moderate Hemophilia by Prophylaxis;<br />

Are We Reach<strong>in</strong>g Our Goal?<br />

den Uijl IEM1,2 , Grobbee DE2 , Fischer K1,2 1Van Creveldkl<strong>in</strong>iek, Dept Haematology, UMC Utrecht, the<br />

Netherlands, 2Julius Center for Health Sciences and Primary<br />

Care, UMC Utrecht, the Netherlands<br />

29P13<br />

International Study Demonstrates the Benefits of Prophylaxis<br />

Coll<strong>in</strong>s P1 , Giangrande P2 , Blanchette V3 , Epste<strong>in</strong> J4 , Xiong<br />

Y4 , Li-McLeod J4 1University Hospital of Wales, Cardiff, United K<strong>in</strong>gdom,<br />

2 3 Churchill Hospital, Oxford, United K<strong>in</strong>gdom, Hospital for<br />

Sick Children, Toronto, ON, Canada, 4Baxter BioScience,<br />

Westlake Village, CA, U.S.A.<br />

29P14<br />

Prophylaxis <strong>in</strong> Hemophilia <strong>in</strong> Tunisia<br />

Gouider E and Meddeb KB<br />

Hemophilia Treatment Centre Aziza Othmana Hospital<br />

Tunisia, Tunis, Tunisia<br />

29P15<br />

Clott<strong>in</strong>g Factor Concentrates Given to Prevent Bleed<strong>in</strong>g and<br />

Bleed<strong>in</strong>g-Related Complications <strong>in</strong> People with Hemophilia<br />

A or B<br />

Iorio A1 , Marches<strong>in</strong>i E1 , Marcucci M1 , Kent S2 1 2 Unversity of Perugia, Perugia, Italy, University of Alberta,<br />

Calgary, AB, Canada<br />

29P16<br />

Prophylaxis <strong>in</strong> Hemophilic Children <strong>in</strong> Poland<br />

Klukowska A, Laguna P, Matysiak M<br />

Dept. Pedriatrics, Hematology and Oncology WUM, Warsaw,<br />

Poland<br />

82<br />

29P17<br />

Prophylaxis with Novoseven® <strong>in</strong> Factor VII Deficiency:<br />

Prelim<strong>in</strong>ary Results from STER (Seven Treatment Evaluation<br />

Registry)<br />

Auerswald G1, Michaels L, Altisent C., Di M<strong>in</strong>no G., Dolce<br />

A., Napolitano M., Mariani G., on behalf of the STER Study<br />

Group<br />

29P18<br />

Comparison of Prophylaxis, On-Demand, or Comb<strong>in</strong>ed<br />

Treatment <strong>in</strong> 20-35 Year Old Males with Severe Hemophilia<br />

<strong>in</strong> 4 European Countries<br />

O’Mahony B, Noone D<br />

Irish Haemophilia Society, Dubl<strong>in</strong>, Ireland<br />

29P19<br />

An Economic Model to Evaluate the Cost-Effectiveness of<br />

Prophylaxis Regimens on Hemophilia Patients with Inhibitors<br />

Knight C1 , Plun-Favreau J2 , Johal S1 1 2 RTI Health Solutions, Zurich, Switzerland, Novo Nordisk,<br />

Zurich, Switzerland<br />

29P20<br />

Long-Term FEIBA Prophylaxis <strong>in</strong> Pediatric Hemophilia A<br />

Patients with High-Titer Inhibitors<br />

Saxena, K1 , Hawk S2 , S<strong>in</strong>gh P2 , Stevens B2 , and Sexauer C2 1 2 Children’s Hospital, Boston, MA, U.S.A. and University of<br />

Oklahoma Children’s Hospital, Oklahoma City, Oklahoma,<br />

U.S.A.<br />

29P21<br />

LA-N8, A New Long-Act<strong>in</strong>g Recomb<strong>in</strong>ant FVIII with<br />

Prolonged Hemostatic Effect <strong>in</strong> a FeCl3 Induced Injury Model<br />

<strong>in</strong> F8-KO Mice<br />

Møller F, Tranholm M, Kjalke M, Thim L, Olsen E,<br />

Jespersgaard C<br />

Novo Nordisk A/S, Maaloev, Denmark<br />

29P22<br />

LA-N8, A New Long-Act<strong>in</strong>g rFVIII with Prolonged Hemostatic<br />

Effect <strong>in</strong> a Mur<strong>in</strong>e Jo<strong>in</strong>t Bleed<strong>in</strong>g Model <strong>in</strong> FVIII-Deficient<br />

Mice<br />

Øvlisen K, Tranholm M, Olsen E, Kjalke M, Thim L, Stennicke H<br />

Novo Nordisk A/S, Maaloev, Denmark<br />

PSYCHOSOCIAL ISSUES<br />

30P17<br />

Systemic Family Therapy: An Effective Tool to Manage<br />

Hemophiliac’s Family Dynamic<br />

Vall<strong>in</strong> Antunes S1 , dos Reis Tomaz M1 , de Morais Horta A2 1Universidade Federal de São Paulo -Depto Oncologia Cl<strong>in</strong>ica<br />

e Experimental, 2Universidade Federal de São Paulo, Depto<br />

de Enfermagem, Brazil

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!